AG
CGEM icon

Artal Group’s Cullinan Oncology CGEM Stock Holding History

Artal Group’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,057,949
Closed -$18.5M – 19
2024
Q2 		$18.5M Buy
+1,057,949
New +$22.5M 0.47% 27
2023
Q3 		– Sell
-250,000
Closed -$2.69M – 107
2023
Q2 		$2.69M Hold
250,000
– – 0.08% 78
2023
Q1 		$2.56M Hold
250,000
– – 0.15% 76
2022
Q4 		$2.64M Hold
250,000
– – 0.15% 78
2022
Q3 		$3.21M Hold
250,000
– – 0.14% 77
2022
Q2 		$3.21M Hold
250,000
– – 0.17% 79
2022
Q1 		$2.62M Hold
250,000
– – 0.11% 106
2021
Q4 		$3.86M Buy
250,000
+150,000
+150% +$2.99M 0.1% 114
2021
Q3 		$2.26M Hold
100,000
– – 0.05% 133
2021
Q2 		$2.58M Hold
100,000
– – 0.05% 133
2021
Q1 		$4.17M Buy
+100,000
New +$4.06M 0.07% 124

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group's CGEM Position: Q3 2024 in Review

Artal Group sold out of Cullinan Oncology (CGEM) in Q3 2024, closing a stake of 1,057,949 shares — an estimated $18.5M sold.

Artal Group first reported a position in CGEM in Q1 2021 and held it in 11 quarters. The position peaked at $18.5M in Q2 2024. 137 funds tracked by Wall St. Rank hold CGEM as of Q3 2024.

  • Artal Group reported no remaining Cullinan Oncology position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 1,057,949 Cullinan Oncology shares in Q3 2024, an estimated $18.5M.
  • Artal Group first reported a position in Cullinan Oncology in Q1 2021 and held it in 11 quarters.
  • Artal Group's Cullinan Oncology position peaked at $18.5M in Q2 2024.
  • 137 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.